CXCR4 and neoplasm: In a preclinical study, Bao et al. demonstrated a synergistic effect of a combination of CXCR4 antagonists (AMD3100) and radioligand therapies targeting cancer-associated fibroblasts (CAFs)- 177Lu-DOTAGA.(SA.FAPi)2 in tumor models of TNBC.